The ingredient, explained

Bisabolol

An ingredient studied as part of a topical combination for epidermal melasma.

EmollientAnti-inflammatoryMaskingSkin conditioningSoothing

Ingredient guide

What it is and what it does

-R*,R*--.alpha.,4-dimethyl-.alpha.--4-methyl-3-pentenyl-cyclohex-3-ene-1-methanol; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha--4-methyl-3-pentenyl--, -theta,theta---+/---; 3-Cyclohexene-1-methanol, alpha,4-dimethyl-alpha--4-methyl-3-pentenyl--, -S--theta,theta--- -levomenol-

About this ingredient: EU CosIng ingredient registry (via Open Beauty Facts taxonomy) ↗

Emollient: Helps soften and smooth the skin surface.
Anti-inflammatory: Research category concerning reduced inflammation. A discovery tag does not establish that an ingredient treats inflammation at the amount used in a product.
Masking: Reduces or conceals the formula's underlying odour or taste.
Skin conditioning: A broad cosmetic role for maintaining skin condition. It does not identify a particular clinical benefit.
Soothing: A technical role associated with relieving skin or scalp discomfort.

Function definitions: European Commission ingredient function definitions (SCCNFP/0299/00, pages 16 to 20) ↗ · National Cancer Institute: Anti-inflammatory definition ↗

Registry functions describe possible formulation roles, not results for a finished product. A dictionary entry is not an approval or a safety assessment.

A closer look

What the research shows

Human research on a combination

An open-label, single-arm study evaluated a cream with 1% bisabolol, 3% arbutin, 4% nicotinamide and 0.05% retinaldehyde. Melasma scores and measured surface area decreased during treatment.

What this does not tell us

The study had no control group and cannot isolate bisabolol. The abstract does not report sample size or treatment duration. It does not establish a general anti-inflammatory or sensitive-skin benefit for another product.

Sources for this summary. PubMed 26682557 ↗

Research review checked Sep 30, 2026

Selected primary sources were reviewed for the existing research brief on 30 September 2026, with exact ingredient, route and combination limitations recorded. This was a bounded editorial review, not a systematic search.